je.st
news
Tag: merck
Merck to Acquire Cubist Pharmaceuticals for $102 Per Share in Cash
2014-12-08 13:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. & LEXINGTON, Mass. Acquisition Augments Mercks Strong Foundation and Opportunity for Growth in Hospital Acute Care Market KENILWORTH, N.J. & LEXINGTON, Mass.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) today announced that the companies have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash, which represents a 35 percent premium to Cubists average stock price for the most recent five trading days. Language: English Contact: MerckMedia Contacts:Lainie Keller, 908-406-1459orSteve Cragle, 908-740-1801orInvestor Contacts:Joe Romanelli, 908-740-1986orJustin Holko, 908-740-1879orCubistMedia Contact:Julie DiCarlo, 781-860-8063orInvestor Contact:Eileen C. McIntyre, 781-860-8100 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: CBST Exchange: NASDAQ read more
Tags: share
cash
acquire
pharmaceuticals
Merck in talks to acquire Cubist Pharmaceuticals for more than $7 billion - NYT
2014-12-06 06:44:09| Biotech - Topix.net
Merck & Co Inc is in talks to acquire Cubist Pharmaceuticals Inc for more than $7 billion in a deal that could be announced as early as next week, the New York Times reported on Friday, citing people briefed on the matter. Merck will likely pay roughly $100 a share for Cubist, valuing the company that makes drugs to fight superbugs, in the range of $7.5 billion, the people said.
Tags: than
billion
talks
acquire
Merck Announces Increased Quarterly Dividend
2014-11-25 19:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has increased the companys quarterly dividend to $0.45 per outstanding share of the companys common stock, up $0.01 from $0.44 per outstanding share paid last quarter. Payment will be made on Jan. 8, 2015, to stockholders of record at the close of business on Dec. 15, 2014. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036orInvestors:Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: increased
quarterly
announces
dividend
Merck, Iowa firm sign Ebola vaccine licensing deal
2014-11-24 20:15:55| Biotech - Topix.net
Merck & Co., one of the world's top developers and sellers of vaccines, has entered a partnership with a small drug developer to research and manufacture a potential Ebola vaccine now in initial patient testing. The exclusive deal involves a vaccine candidate called rVSV-EBOV that's under early development by BioProtection Systems, the vaccine-development subsidiary of NewLink Genetics Corp. of Ames, Iowa.
Merck Partners With NewLink To Speed Up Work On Ebola Vaccine
2014-11-24 20:15:54| Biotech - Topix.net
A 26-year-old man receives an injection in September of an experimental Ebola vaccine being tested by the National Institute of Allergy and Infectious Diseases and GlaxoSmithKline. Until now, the two leading candidates for a vaccine to protect against the Ebola virus were being led by global pharmaceutical giant GlaxoSmithKline on the one hand, and a tiny company in Ames, Iowa, that was virtually unknown, on the other.
Tags: work
speed
partners
vaccine
Sites : [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] next »